CASI Pharmaceuticals, Inc. director Alex Wu filed an initial ownership report showing equity interests in the company. The filing lists several fully vested stock options to buy Ordinary Shares, including grants covering 11,045, 38,838 and 11,753 underlying shares at an exercise price of $1.93 per share, plus additional options at $2.67, $3.59 and $1.26 per share. Wu also reports direct ownership of 34,168 Ordinary Shares. A footnote states that all of the reported options are fully vested and exercisable as of the date of this form, meaning they can be converted into Ordinary Shares at the stated exercise prices through their respective expiration dates in 2031 through 2035.
CASI Pharmaceuticals’ major holder Wei-Wu He filed Amendment No. 14 to update his beneficial ownership to 18,985,535 ordinary shares, or 53.0% of the class. This percentage is based on 20,555,873 ordinary shares outstanding as of March 20, 2026.
The amendment reflects that ETP Global III Fund L.P., an affiliated fund, purchased a new US$5 million convertible note on February 19, 2026 as the third tranche of a US$20 million convertible note financing. The note may be converted into ordinary shares from the 91st day after issuance until maturity at a price equal to the five-day volume-weighted average closing price, but not above US$2 or below US$1 per share. For reporting purposes, the filing assumes a US$1 conversion price, given an average share price of US$0.15 over the last five trading days, and includes shares that can be acquired within 60 days.
CASI Pharmaceuticals director and over-10% holder Dr. Wei-Wu He has filed a Form 3 reporting his existing stakes in the company. He reports direct ownership of 1,910,550 Ordinary Shares and several option awards to buy additional Ordinary Shares at an exercise price of $1.93 with expirations between 2031 and 2033.
He also reports multiple indirect holdings of Ordinary Shares through entities such as Emerging Technology Partners, ETP funds, HE Family GRAT and the Huiying Memorial Foundation, and specifically disclaims beneficial ownership of shares held by the Foundation.
CASI Pharmaceuticals director James Huang filed a Form 3 reporting his initial ownership position. The filing lists three fully vested stock option awards over CASI ordinary shares: options over 10,000 shares at an exercise price of $1.69 expiring on October 1, 2035, 10,000 shares at $2.69 expiring on May 1, 2033, and 101,571 shares at $1.93 expiring on March 20, 2026. It also reports indirect ownership of 4,529,956 ordinary shares held by Panacea Venture Healthcare Fund II, L.P., an entity associated with Huang. He may be deemed to share beneficial ownership of these shares but explicitly disclaims such beneficial ownership.